This study is testing a new, non-opioid drug called CNTX-3001 for people with chronic, moderate to severe low back pain that hasn't improved with other treatments. This is the first time CNTX-3001 will be given to people, and it will be delivered directly into the spinal fluid (intrathecal space) through a lumbar puncture. Researchers want to see how safe CNTX-3001 is and how well your body handles it. You might receive CNTX-3001 or a placebo (an inactive substance). The study is looking for 16 participants aged 18 to 75 who have tried physical therapy, multiple medications, and other therapies without success. The main goal is to track any side effects from the treatment up to Day 7.

Study design

This is a Phase 1 interventional study, meaning it's an early-stage trial testing a new treatment in people for the first time. It plans to enroll 16 participants.

What's involved

Not specified in the trial record.

Compensation

Not stated in the trial record.

Follow-up

The primary safety endpoint is measured from baseline to the end of treatment visit (Day 7).

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.